Mirum Pharmaceuticals/$MIRM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
- Ticker
- $MIRM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 470
- Headquarters
- Foster City, United States
- Website
- www.mirumpharma.com
MIRM Metrics
BasicAdvanced
$6.1B
-
-$15.12
0.74
-
Price and volume
Market cap
$6.1B
Beta
0.74
52-week high
$130.00
52-week low
$63.23
Average daily volume
732K
Financial strength
Current ratio
2.072
Quick ratio
1.872
Long term debt to equity
-13.675
Total debt to equity
-13.722
Interest coverage (TTM)
-12.68%
Profitability
EBITDA (TTM)
-118.305
Gross margin (TTM)
81.72%
Net profit margin (TTM)
-134.75%
Operating margin (TTM)
-21.63%
Effective tax rate (TTM)
-0.39%
Revenue per employee (TTM)
$1,430,000
Management effectiveness
Return on assets (TTM)
-10.01%
Return on equity (TTM)
-760.01%
Valuation
Price to revenue (TTM)
8.325
Price to book
-112.32
Price to tangible book (TTM)
-18.45
Price to free cash flow (TTM)
-18.082
Free cash flow yield (TTM)
-5.53%
Free cash flow per share (TTM)
-5.162
Growth
Revenue change (TTM)
42.18%
Earnings per share change (TTM)
1,701.26%
3-year revenue growth (CAGR)
66.73%
3-year earnings per share growth (CAGR)
52.22%
What the Analysts think about MIRM
Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.
Analyst projections of the future price of Mirum Pharmaceuticals stock.
Bulls say / Bears say
Mirum’s commercial base is growing quickly: Q3 product sales reached $185.7 million and management raised its 2026 sales guidance to $715–720 million, with Livmarli sales up 45% year on year. (Mirum Pharmaceuticals)
The FDA approved and Mirum launched ATEBRIOZ for FOP, giving it a new commercial product; follow-up paediatric data also support the potential to extend treatment to younger patients. (Mirum Pharmaceuticals, Mirum Pharmaceuticals)
Brelovitug cleared a major hurdle in hepatitis D: its AZURE-1 Phase 3 trial met the main endpoint, with 45%–56% of treated patients meeting the combined response versus none in the delayed-treatment group. (Reuters)
Volixibat’s path to market has become less certain: despite positive Phase 2b results in PSC, the FDA recommended a Phase 3 trial, delaying Mirum’s potential NDA submission to H1 2027. (Mirum Pharmaceuticals)
Spending is running ahead of sales: Q3 operating expenses were $245.5 million against $185.7 million in revenue, so Mirum still needs to fund substantial development and commercial costs. (Mirum Pharmaceuticals)
Volixibat also showed potential tolerability concerns: gastrointestinal events and liver-enzyme elevations occurred more often than with placebo in the PSC study, which could complicate treatment use or approval. (Mirum Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
MIRM Financial Performance
Revenues and expenses
MIRM Earnings Performance
Company profitability
Upcoming events
No upcoming events
MIRM News
AllArticlesVideos
Mirum's liver infection drug lowers virus levels in second late-stage study
Reuters3 days ago
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
Business Wire3 days ago
Mirum Pharmaceuticals Q3 Earnings Call Highlights
MarketBeat1 week ago
Funds containing MIRM
Fund name | Fund size | $MIRM weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.39% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.39% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.15% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.15% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.